Ken Griffin Sellas Life Sciences Group, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 459,900 shares of SLS stock, worth $740,439. This represents 0.0% of its overall portfolio holdings.
Number of Shares
459,900
Previous 264,600
73.81%
Holding current value
$740,439
Previous $285,000
253.33%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding SLS
# of Institutions
84Shares Held
22.6MCall Options Held
1.3MPut Options Held
59.3K-
Vanguard Group Inc Valley Forge, PA6.65MShares$10.7 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.72MShares$4.37 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.2MShares$3.54 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA1.49MShares$2.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.13MShares$1.81 Million0.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $33.1M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...